Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BINV.STthis companyBioInvent International AB (publ)	SEK 2.95	-5.81×	3.47×	8.54×	-4.79×	-4108.5%	100.0%	-155.1%	-147.0%	-59.7%	-62.1%	-13.2%	0.02×	1.05×	0×	5.67×	0.0%	3	-2.93	1	C-
CANTA.STCantargia AB (publ)	SEK 1.55	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
DMYD-B.STDiamyd Medical AB (publ)	SEK 0.98	-0.58×	0.61×	310.44×	0.62×	98.3%	-478.8%	-54562.9%	-53583.4%	-104.9%	-78.6%	-132.6%	0×	1.21×	-73.88×	9.08×	0.0%	3	-0.68	2	B-
DVYSR.STDevyser Diagnostics AB (publ)	SEK 64.90	-223.92×	5.35×	7.56×	49.58×	-193.5%	80.6%	4.2%	-3.4%	-2.4%	2.6%	0.4%	0.15×	-0.68×	0.78×	2.88×	0.0%	7	6.42	2	C+
EGTX.STEgetis Therapeutics AB (publ)	SEK 11.12	-5.74×	5.81×	31.51×	-5.36×	-144.1%	19.9%	-555.9%	-548.9%	-101.1%	-79.2%	-13.7%	0.27×	0.36×	-15.28×	1.05×	0.0%	5	4.55	1	C-
HNSA.STHansa Biopharma AB (publ)	SEK 41.30	-5.22×	-31.35×	12.55×	-6.25×	-323.4%	62.4%	-234.3%	-240.3%	600.2%	-57.8%	-19.7%	-10.49×	-0.48×	-4.43×	1.94×	0.0%	2	-0.05	2	C
Peer median	—	-5.22×	3.91×	12.55×	0.62×	-144.1%	62.4%	-234.3%	-240.3%	-2.4%	-57.8%	-13.7%	0×	-0.48×	-4.43×	2.88×	0.0%	5	3.27	2	—